Siponimod is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Siponimod Fumaric Acid was developed by Novartis Ag.
The API has now reached off-patent status, after being launched in 2019.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Siponimod Fumaric Acid and many others, contact info@pharmacheminvestor.com